RxDoctor Payments Data

Deep Phachu, MD

Nephrology · Worcester, MANPI 1912435736

Payments from drug & device makers

$1,903in general payments, 2019–2025

Across 82 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$303
  • GSK$268
  • Mallinckrodt Hospital Products Inc.$206
  • Amgen$185
  • AstraZeneca$139
  • Akebia Therapeutics Inc$124
  • plus $679 from 11 others

What the payments were for

  • Food & beverage$1,79194%
  • Education$1136%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,903 in reported general payments places this provider in the 65th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$190,114
Medicare patients
423
Services billed
3,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$36,978
FarxigaDapagliflozin Propanediol14$16,573
Potassium Citrate ErPotassium Citrate25$2,459
Bumetanide33$1,664
Calcitriol46$1,512
Calcium Acetate11$1,428
Nifedipine ErNifedipine31$1,102
Amlodipine-ValsartanAmlodipine Besylate/Valsartan18$1,015
Amlodipine Besylate109$955
Spironolactone32$765
Doxazosin Mesylate38$559
Tamsulosin Hcl23$539
Hydralazine Hcl27$521
Losartan Potassium53$468
Chlorthalidone23$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$24$36,97827 claims
AstraZenecaFarxiga$139$16,57314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 339 nephrology providers in Massachusetts.

Other nephrology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →